Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J; Nordic Myeloma Study Group. Mellqvist UH, et al. Among authors: juliusson g. Cancer. 2008 Jan 1;112(1):129-35. doi: 10.1002/cncr.23145. Cancer. 2008. PMID: 17973267 Free article. Clinical Trial.
Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.
Osterborg A, Ahre A, Björkholm M, Björeman M, Brenning G, Gahrton G, Gyllenhammar H, Johansson B, Juliusson G, Järnmark M, et al. Osterborg A, et al. Among authors: juliusson g. Eur J Haematol. 1989 Jul;43(1):54-62. doi: 10.1111/j.1600-0609.1989.tb01252.x. Eur J Haematol. 1989. PMID: 2670605 Clinical Trial.
Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.
Björkholm M, Liliemark J, Gahrton G, Grimfors G, Gruber A, Hast R, Juliusson G, Järnmark M, Killander A, Kimby E, et al. Björkholm M, et al. Among authors: juliusson g. Eur J Haematol. 1995 Jul;55(1):19-23. doi: 10.1111/j.1600-0609.1995.tb00228.x. Eur J Haematol. 1995. PMID: 7615046 Clinical Trial.
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: juliusson g. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma.
Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wislöff F; Nordic Myeloma Study Group. Waage A, et al. Among authors: juliusson g. Br J Haematol. 2004 Apr;125(2):149-55. doi: 10.1111/j.1365-2141.2004.04879.x. Br J Haematol. 2004. PMID: 15059136 Free article. Clinical Trial.
Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival.
Juliusson G, Billström R, Gruber A, Hellström-Lindberg E, Höglunds M, Karlsson K, Stockelberg D, Wahlin A, Aström M, Arnesson C, Brunell-Abrahamsson U, Carstensen J, Fredriksson E, Holmberg E, Nordenskjöld K, Wiklund F; Swedish Adult Acute Leukemia Registry Group. Juliusson G, et al. Leukemia. 2006 Jan;20(1):42-7. doi: 10.1038/sj.leu.2404004. Leukemia. 2006. PMID: 16327841
285 results